New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2012
16:18 EDTKO, GS, JNJ, SRSL, DTSI, FSLR, AMTG, WHROn The Fly: Closing Wrap
Stocks on Wall Street were significantly higher, as a trio of earnings reports and a boost in the IMF's view of global growth prospects powered the market's rise. Stock futures were higher in pre-market trading on the strength of positive earnings reports from Coca-Cola (KO), Goldman Sachs (GS), and Johnson & Johnson (JNJ). The domestic economic data, which included fewer than expected housing starts and no increase in industrial production, was overshadowed by increased global and U.S. growth forecasts by the International Monetary Fund. With the earnings season beginning in earnest this week, investors appeared bullish about the prospects for solid numbers this quarter, if today's trading is taken as an indication... ECONOMIC EVENTS: In the U.S., housing starts for the month of March decreased 5.8%, versus expectations of an increase of 1%, but the number of building permits issued rose 4.5%, versus expectations of a decrease of 0.7%. Industrial production was reportedly flat in March, versus expectations for a 0.3% increase. Capacity utilization was in line with forecasts at 78.6%. In Europe, a German investor confidence survey was better than expected and Spanish benchmark yields eased back below 6%. Also, the International Monetary Fund said it sees world output growing 3.5% in 2012, raising its projection for United States growth to 2.1%. The IMF also said it sees growth in China slowing to 8.2% and real GDP in the euro area contracting in the first half of 2012 but then recovering... COMPANY NEWS: Coca Cola and Goldman Sachs both reported earnings and revenue that beat the Street's expectations, though Coke saw more of a favorable reaction from investors. Coca Cola shares rose 2.08% to $73.95 after its report, while Goldman fell 0.74% to $116.86. Johnson and Johnson also beat consensus for adjusted earnings, but its revenue came in below forecasts. Shares rose 0.38% to $64.22, making it one of the Dow's laggards during a session that saw all 30 stocks in the index post gains... MAJOR MOVERS: Among the notable gainers were SRS Labs (SRSL), up $2.53, or 36.88%, to $9.39, after agreeing to be acquired by DTS, Inc. (DTSI) in a cash-and-stock transaction valued at $9.50 per share, and First Solar (FSLR), up $2.14, or 10.28%, to $22.96, following its announcement of plans to cut its global workforce by approximately 2,000 positions, or about 30%, in response to conditions in Europe. Noteworthy losers included Apollo Residential Mortgage (AMTG), down $1.37, or 7.16%, to $17.76, after filing to sell 13.9M shares of its common stock, and Whirlpool (WHR), down $3.03, or 4.27%, to $68.00, after the International Trade Commission voted against imposing duties on refrigerators produced in South Korea and Mexico... INDICES: The Dow gained 194.13, or 1.50%, to 13,115.54; the Nasdaq rose 54.42, or 1.82%, to 3,042.82; and the S&P 500 added 21.21, or 1.55%, to 1,390.78.
News For KO;GS;JNJ;SRSL;DTSI;FSLR;AMTG;WHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 13, 2014
10:08 EDTWHR, DTSIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:40 EDTDTSIDTS, Inc. upgraded to Buy from Neutral at Dougherty
Subscribe for More Information
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:25 EDTJNJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:15 EDTJNJ, GSNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
06:47 EDTWHRWhirlpool upgraded to Buy from Neutral at Longbow
Subscribe for More Information
06:44 EDTGSRegulators seeking banks' auto loan data, Reuters reports
Subscribe for More Information
06:37 EDTGSBlackRock, Morgan Stanley to buy shares in Link Net, WSJ reports
Subscribe for More Information
October 12, 2014
13:03 EDTGSBanks agree on derivatives procedures for future crisis scenario, WSJ says
Meeting at the Federal Reserve in Washington, top banking executives from 18 large U.S., European and Japanese banks agreed in principle to wait up to 48 hours before seeking to terminate derivatives contracts and collect associated payments from a troubled financial institution, says the Wall Street Journal. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
October 10, 2014
10:01 EDTJNJOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:19 EDTJNJMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
08:15 EDTJNJJohnson & Johnson reports additional data from ATTAIN study
Subscribe for More Information
07:07 EDTJNJJohnson & Johnson upgraded to Neutral from Underperform at Credit Suisse
Subscribe for More Information
06:49 EDTWHRWhirlpool risks from Sears exposure overstated, says BofA/Merrill
BofA/Merrill said Whirlpool (WHR) concerns from Sears (SHLD) exposure are overdone and notes total revenues from Sears are approximately 9% of North American revenues. Shares are Buy rated.
06:27 EDTJNJJohnson & Johnson upgraded to Neutral from Underperform at Credit Suisse
October 9, 2014
10:38 EDTKOPepsiCo climbs after results beat estimates, outlook raised
Subscribe for More Information
09:25 EDTFSLRFirst Solar reiterated as a Sell at Goldman
Subscribe for More Information
08:21 EDTGSGoldman, Credit Suisse invest in digital surveillance start-up, Bloomberg says
A group of banks, led by Goldman Sachs (GS) and Credit Suisse (CS), invested $24M in Digital Reasoning, a data analytics start-up whose CEO, Tim Estes, said the banks want a way to surveil millions of e-mails, instant messages, and transcripts of calls to spot suspicious behavior "when it happens, not in an investigation three years later.” Reference Link
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use